

August 12, 2023

Listing Department Code: 532321

**BSE LIMITED** 

P J Towers, Dalal Street, Mumbai–400 001

Listing Department Code: ZYDUSLIFE

### **NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, C/1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai-400 051

Re.: Newspaper publication

Dear Sir / Madam,

Please find attached the newspaper cutting with regard to publication of extracts of unaudited financial results for the quarter ended on June 30, 2023 in Financial Express on August 12, 2023.

Please find the same in order.


Thanking you,

Yours faithfully, For, **ZYDUS LIFESCIENCES LIMITED** 

DHAVAL N. SONI COMPANY SECRETARY

Encl.: As above

# FINANCIAL EXPRESS



# Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN: L24230GJ1995PLC02587


Sr. No.	Extract of Consolidated Unaudited Financial Results f	SANS FOR STATE OF STA	Rupees in Million				
	Particulars	LOUIS TO SERVICE THE	3 Months ended 30/06/2023	Preceding 3 Months ended 31/03/2023		Previous year ended 31/03/2023	
10 500	THE RESIDENCE OF THE PARTY OF T		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
10	Total Income from operations	STATE OF	51,396	50,106	39,643	172,374	
2	Net Profit for the period before exceptional items and tax	TO SERVICE	13,434	10,871	6,839	31,939	
3	Net Profit for the period after exceptional items but before tax	S. D. W.	13,292	4,858	6,810	25,897	
4	Net Profit for the period from continuing operations		10,879	2,988	5,266	19,649	
5	Loss after tax from discontinued operations		(10)	(22)	(83)	(46)	
6	Net Profit for the period after tax and Non-Controlling Interest		10,869	2,966	5,183	19,603	
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	FOR PELLIN	10,931	3,015	3,608	16,459	
8	Paid-up equity share capital (Face value Re. 1/-)	6 3 7 7 7	1,012	1,012	1,024	1,012	
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)					174,146	
10	Earnings per share for continuing operations (not annualised for the quarter)		THE REAL PROPERTY.	LINSHOT DEPTH	<b>新加州村(10)</b>	HERE TENDED TO	
	Basic (Rs.)		10.75	2.95	5.14	19.35	
ь	Diluted (Rs.)	THE STATE OF	10.75	2.95	5.14	19.35	
1 300	Earnings per share for continuing & discontinued operations (not annualised for the quarte	0	THE REAL PROPERTY.				
	Basic (Rs.)		10.74	2.93	5.06	19.30	
b	Diluted (Rs.)	The state of the state of	10.74	2.93	5.06	19.30	

### Note

[1] The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

By Order of the Board, For Zydus Lifesciences Limited,

Date: August 11, 2023 Place: Ahmedabad Dr. Sharvil P. Patel Managing Director DIN: 00131995



### Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Valshnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN: L24230GJ1995PLC025878

Sr. No.		Rupees in Million				
	Particulars	3 Months ended 30/06/2023	Preceding 3 Months ended 31/03/2023	Corresponding 3 Months ended 30/06/2022 in the previous year		
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
1	Total Income from operations	51,396	50,106	39,643	172,374	
2	Net Profit for the period before exceptional items and tax	13,434	10,871	6,839	31,939	
3	Net Profit for the period after exceptional items but before tax	13,292	4,858	6,810	25,897	
4	Net Profit for the period from continuing operations	10,879	2,988	5,266	19,649	
5	Loss after tax from discontinued operations	(10)	(22)	(83)	(46	
6	Net Profit for the period after tax and Non-Controlling Interest	10,869	2,966	5,183	19,603	
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	10,931	3,015	3,608	16,459	
8	Pald-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,024	1,012	
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)			Control of the	174,146	
10	Earnings per share for continuing operations (not annualised for the quarter)	in the second	Design look in		-	
a	Basic (Rs.)	10.75	2.95	5.14	19.35	
b	Diluted (Rs.)	10.75	2.95	5.14	19.35	
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter)					
	Racio (De )	10.74	2.93	5.06	19.30	
	Diluted (Rs.)	10.74	2.93	5.06	19.30	

3

[1] The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindla.com] and on the website of NSE [www.nseindla.com].

Trinches will be

By Order of the Board, For Zydus Lifesciences Limited,

> Dr. Sharvil P. Patel Managing Director DIN: 00131995

Date: August 11, 2023 Place: Ahmedabad